FealtySign in
Promise-keeping streak3 kept in a rowguidance & buyback

CARDINAL HEALTH INC

(CAH)

CIK 721371 · SEC filings only

Not gradedDividend record
shown as history
company entity
53 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

53 declarations · 18 raised · 34 held · 0 cut · held 52 quarters

  1. HELD$0.5107/shperiod ended 2025-12-31Filing ↗
  2. RAISED$0.5107/shperiod ended 2025-09-30Filing ↗
  3. HELD$0.5056/shperiod ended 2025-03-31Filing ↗
  4. HELD$0.5056/shperiod ended 2024-12-31Filing ↗
  5. RAISED$0.5056/shperiod ended 2024-09-30Filing ↗
  6. HELD$0.5006/shperiod ended 2024-03-31Filing ↗
  7. HELD$0.5006/shperiod ended 2023-12-31Filing ↗
  8. RAISED$0.5006/shperiod ended 2023-09-30Filing ↗
  9. HELD$0.4957/shperiod ended 2023-03-31Filing ↗
  10. HELD$0.4957/shperiod ended 2022-12-31Filing ↗
  11. RAISED$0.4957/shperiod ended 2022-09-30Filing ↗
  12. HELD$0.4908/shperiod ended 2022-03-31Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
3 resolved promises

Sector median (Trade & Services): A+ across 14 graded companies

Not enough resolved promises to grade

3 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Open promises (3)

Open · buyback authorization

raising its share repurchase expectations in fiscal year 2025 by $250 million to a total of $750 million

next filing due$750.0000receipt (opens in a new tab)
Open · buyback authorization

Share repurchases ~$750 million

resolves in ~289 days$750.0000receipt (opens in a new tab)
Open · buyback authorization

Cardinal Health Board of Directors approved a $5.0 billion increase to the share repurchase program

resolves in ~654 days$5.0000receipt (opens in a new tab)

Credibility timeline

KEPT · Feb 1, 2024KEPT · Nov 1, 2024KEPT · Aug 11, 2026
20242026
Timeline as a list
  • Feb 1, 2024KEPTBoard of Directors approved a 3-year authorization to repurchase up to an additional $3 billion of Cardinal Health common shares
  • Nov 1, 2024KEPTShare repurchases $1.5B - $2.0B
  • Aug 11, 2026KEPTBaseline share repurchases $500M
3 resolved buyback promises · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
Not yet gradedGuidance record
harness minimum not met
company entity
0 resolved promises

Sector median (Trade & Services): A+ across 26 graded companies

Not enough comparable guidance to grade

0 of the 4 resolved guidance promises needed to publish a reliability grade. Some of this company’s guidance has no reported figure we can compare it with. It is shown below, never scored; the line under each statement says why. Here's what we're tracking — we never show a grade we can't back with receipts.

Pro

guidance history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

8 of 8 guidance figures that were graded or dropped for basis could not be graded on the same basis (100%). Guidance marked “not judged” is in neither number.

Guidance typeSaidGradedDroppedOther
EPS · non-GAAPcannot be graded380830

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (38)

We show what was said — with its source filing — but never score it. The line under each statement says why.

  1. eps guidance fy · Aug 11, 2026
    Cardinal Health provides fiscal year 2027 non-GAAP EPS guidance 2 of 13% to 15% growth 3 ($12.40 to $12.60)
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Apr 30, 2026
    Cardinal Health is raising and narrowing its fiscal year 2026 guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $10.70 to $10.80
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Feb 5, 2026
    Cardinal Health is raising its fiscal year 2026 guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $10.15 to $10.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Oct 30, 2025
    Cardinal Health is raising its guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $9.65 to $9.85
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Aug 12, 2025
    The company raised its fiscal year 2026 outlook for non-GAAP diluted EPS to $9.30 to $9.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · May 1, 2025
    raised and narrowed to $8.05 to $8.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · May 1, 2025
    Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Jan 30, 2025
    The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $7.85 to $8.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Nov 1, 2024
    The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $7.75 to $7.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Aug 14, 2024
    Fiscal year 2025 non-GAAP EPS guidance raised to $7.55 to $7.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · May 2, 2024
    raised and narrowed to $7.30 to $7.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · May 2, 2024
    at least $7.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Feb 1, 2024
    Fiscal 2024 non-GAAP EPS guidance raised to $7.20 to $7.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Nov 3, 2023
    The company raised its fiscal 2024 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $6.75 to $7.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Aug 15, 2023
    Fiscal year 2024 non-GAAP EPS guidance raised to $6.50 to $6.75
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · May 4, 2023
    Fiscal year 2023 non-GAAP EPS guidance raised and narrowed to $5.60 to $5.80
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Feb 2, 2023
    The company updated its fiscal year 2023 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.20 to $5.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Nov 4, 2022
    The company reaffirmed its fiscal year 2023 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. of $5.05 to $5.40.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Aug 11, 2022
    Non-GAAP earnings per share $5.05 - $5.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · May 5, 2022
    The company updated its fiscal year 2022 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.15 to $5.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Feb 3, 2022
    The company updated its fiscal year 2022 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.15 to $5.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · Nov 9, 2021
    The company reaffirmed its fiscal year 2022 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. of $5.60 to $5.90.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance fy · Aug 5, 2021
    Non-GAAP earnings per share $5.60 - $5.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · May 6, 2021
    Cardinal Health narrowed its fiscal year 2021 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.90 to $6.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · Feb 5, 2021
    Cardinal Health raised its fiscal year 2021 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.85 to $6.10
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Nov 5, 2020
    Cardinal Health is updating its fiscal year 2021 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.65 to $5.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. eps guidance fy · May 3, 2012
    revised range of $3.15 to $3.20 for fiscal 2012 non-GAAP diluted earnings per share from continuing operations
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  28. eps guidance fy · Oct 27, 2011
    The company reaffirmed its fiscal 2012 outlook for non-GAAP diluted earnings per share of $3.04 to $3.19.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. eps guidance fy · Apr 28, 2011
    we are increasing our full-year guidance for non-GAAP diluted EPS from continuing operations to $2.61 to $2.67
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. eps guidance fy · Oct 28, 2010
    we have become more confident in achieving the higher end of our non-GAAP diluted EPS guidance range of $2.38 to $2.48
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. eps guidance fy · Apr 29, 2010
    preliminary view of fiscal 2011 non-GAAP diluted EPS from continuing operations is in the range of $2.35 to $2.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  32. eps guidance fy · Apr 29, 2010
    non-GAAP diluted EPS from continuing operations for fiscal 2010 will be in the range of $2.15 to $2.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  33. eps guidance fy · Nov 5, 2009
    we expect that our full-year performance will likely be toward the higher end of our guidance of $1.90 to $2.00 for non-GAAP diluted EPS from continuing operations
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  34. eps guidance fy · Apr 30, 2009
    we are maintaining our full-year non-GAAP EPS outlook within, but at the low end of, our guidance range of $3.50 to $3.60 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  35. eps guidance fy · Jan 8, 2009
    we anticipate full-year non-GAAP EPS to be in a range of $3.50 to $3.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  36. eps guidance q · Jan 8, 2009
    Non-GAAP diluted EPS from continuing operations 1 for the company’s fiscal second quarter, ended Dec. 31, 2008, is anticipated to be at least $0.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  37. eps guidance fy · Jul 8, 2008
    non-GAAP diluted earnings per share from continuing operations 1 for fiscal 2008 are expected to be about in the middle of a $3.75 to $3.85 range
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  38. eps guidance fy · Jan 29, 2008
    Cardinal Health now expects non-GAAP EPS to be in a range of $3.75 to $3.85 for the year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
0 resolved guidance promises · 38 not graded (no comparable reported figure) · resolver resolver-v5 · score score-v1. Every verdict links to its source filing. Full methodology →